GFAP anticorps (Intracellular) (Atto 647N)

N° du produit ABIN7582030

Cet anticorps Lapin Polyclonal détecte spécifiquement GFAP dans IHC et IC. Il présente une réactivité envers Rat.

Aperçu rapide pour GFAP anticorps (Intracellular) (Atto 647N) (ABIN7582030)

Antigène: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Reactivité: Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp GFAP est conjugé à/à la Atto 647N

Application: Immunohistochemistry (IHC), Immunochromatography (IC)

Détail du produit anti-GFAP anticorps (Atto 647N)

Épitope: AA 27-39, Intracellular

Fonction: A Rabbit Polyclonal Antibody to GFAP conjugated to the fluorescent dye ATTO Fluor-647N

Séquence: (C)RHLGTIPRLS LSR

Specificité: Intracellular, cytoplasm

Homologie: Mouse - 10,13 amino acid residues identical The antibody will not recognize human GFAP

Attributs du produit: Anti-GFAP Antibody (ABIN7043217, ABIN7044273 and ABIN7044274) is a highly specific antibody directed against an epitope of the rat GFAP protein. The antibody can be used in western blot and immunohistochemistry applications. It has been designed to recognize GFAP from rat and mouse samples. The antibody will not recognize human GFAP. Anti-GFAP-ATTO Fluor-647N Antibody (ABIN7043217, ABIN7044273 and ABIN7044274-FRN) is directly conjugated to the ATTO Fluor-647N fluorophore. This conjugated antibody has been developed to be used in immunofluorescent applications such as multicolor immunohistochemistry and immunocytochemistry. It has been designed to recognize GFAP from mouse and rat samples. The antibody will not recognize human GFAP. ATTO Fluor 647N belongs to a new generation of fluorescent labels for the red spectral region. Characteristic features of the label are strong absorption, high fluorescence quantum yield, high thermal and photo-stability, and exceptionally high stability towards atmospheric ozone. Thus ATTO Fluor 647N is highly suitable for single-molecule detection applications and super-resolution microscopy techniques such as Structured Illumination Microscopy (SIM), Stimulated Emission Depletion (STED), etc.

Purification: Affinity purified on immobilized antigen.

Immunogène: (C)RHLGTIPRLSLSR, corresponding to amino acid residues 27-39 of rat Glial fibrillary acidic protein

Isotype: IgG

Information d'application

Indications d'application:

Antigen preadsorption control: 1 μg peptide per 1 μg antibody

Application Dilutions Immunohistochemistry paraffin embedded sections ihc: 1:80-1:100

Application Dilutions Western blot wb: N/A

Commentaires:

Negative Control: (ABIN7582045)

Blocking Peptide: (ABIN7235599)

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Reconstitution: 50 μL double distilled water (DDW).

Concentration: 1 mg/mL

Buffer: PBS pH 7.4, 1 % BSA with 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire:

Storage before reconstitution: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.

Storage after reconstitution: The reconstituted solution can be stored at 4°C, protected from the light, for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).

Détails sur GFAP

Antigène: GFAP (Glial Fibrillary Acidic Protein (GFAP))

Autre désignation: GFAP

Sujet: Glial fibrillary acidic protein,Glial fibrillary acidic protein (GFAP) is a key intermediate filament (IF) III protein responsible for maintaining the mechanical strength of glia cells by supporting their cytoskeleton structure. GFAP is expressed in astrocytes in the CNS, non-myelinating Schwann cells in the PNS, and enteric glial cells1.GFAP has a structural organization that is typical to class III IF proteins: it has a head, rod, and tail domains. The N-terminal head domain is important for filament formation and the C-terminal domain is important for oligomerization2.GFAP is encoded by a single gene mapped to human chromosome 17q21. To date, 10 isoforms/splice variants have been identified. GFAP is tightly regulated: both at mRNA transcription level and by phosphorylation and other post-translational modifications. A number of growth factors such as CNTF, FGF and TGF-β can induce GFAP gene transcription activation leading to increased GFAP protein levels3.Single nucleotide polymorphism (SNP) in GFAP results in the formation of Rosenthal fibers that cause Alexander Disease, hence, GFAP is a potential drug target for the treatment of this disease. A number of GFAP mutations were found in the coding and in the promoter regions of Alexander disease patients4.GFAP gene activation and protein induction appear to play a critical role in astroglia cell activation (astrogliosis) following CNS injuries and neurodegeneration. GFAP protein and its breakdown products are rapidly released into biofluids following traumatic brain and spinal cord injuries and stroke, making them strong candidate biomarkers for such neurological disorders5.

ID gène: 24387

UniProt: P47819